Navigation Links
BUSM researchers study epigenetic mechanisms of tumor metastasis for improved cancer therapy
Date:10/30/2013

A review article by researchers at Boston University School of Medicine (BUSM) suggests that epigenetics may be a useful target to stop the growth, spread and relapse of cancer. The findings are published online in Volume 14 of the International Journal of Molecular Science.

The term epigenetics refers to the external modifications to DNA that turn genes "on" or "off." These modifications do not change the DNA sequence, but instead, they affect how cells read genes.

The researchers propose that epigenetic and other changes mediate the development of cancer progenitor cells. These cells represent the early stage of cancer cell development and can grow rapidly to become full-fledged cancer. According to the researchers, progression of different cancer stages and development of metastatic potential requires differentiation of these cancer progenitor cells.

"These findings are not only important in understanding how cancer progresses, but also help in understanding how cancer progenitor cells grow and differentiate via epigenetic regulators," said Sibaji Sarkar, PhD, instructor of medicine at BUSM.

Mutated cells are more vulnerable to the environment. Some of these mutations may alter epigenetic regulation in addition to epigenetic changes occurring by external and internal influences, which impacts gene expression and regulates cell behavior, playing a profound role when normal cells develop into progenitor cancer cells.

Sarkar and his colleagues hypothesize that when the progenitor cancer cells metastasize, rapid growth halts. When differentiation is complete, the rapid growth resumes.

The researchers believe that epigenetic mechanisms are involved in this process. Once a degree of metastatic form of cancer is achieved, the genes, which cause the change, become inactive and the genes causing rapid growth are again turned on.

"The acknowledgement of epigenetic changes as key regulators of this switching is expected to generate better epigenetic drugs. It has been suggested that epigenetic drug treatment in combination with standard chemotherapeutic drugs may have better outcomes in preventing and treating drug-resistant cancers," he added.


'/>"/>

Contact: Gina Orlando
gina.orlando@bmc.org
617-638-8490
Boston University Medical Center
Source:Eurekalert

Related biology news :

1. Researchers quantify toxic ocean conditions during major extinction 93.9 million years ago
2. Researchers discover how cancer invisibility cloak works
3. Oregon researchers say supplement cuts muscle loss in knee replacements
4. BUSM researchers identify molecule that could aid lung cancer detection, treatment
5. Researchers identify gene variant that raises risk for colorectal cancer from eating processed meat
6. Researchers show how plants tell the time
7. Berkeley Lab researchers get a detailed look at a DNA repair protein in action
8. Researchers capture images of open channel that moves proteins across cell membranes
9. UAlberta medical researchers discover potential new treatment for colitis
10. Older siblings cells can be passed from female dogs to their puppies in the womb, MU researchers find
11. Nitrogen fertilizer remains in soils and leaks towards groundwater for decades, researchers find
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2016)... The Department of Transport Management (DOTM) of ... Dollar project, for the , Supply and Delivery ... IT Infrastructure , to Decatur ... Identity Management Solutions. Numerous renowned international vendors participated in the ... was selected for the most compliant and innovative solution. The ...
(Date:5/24/2016)... facilitates superior patient care by providing unparalleled technology to leaders of the medical imaging ... product recently added to the range of products distributed by Ampronix. Photo ... ... ... News ...
(Date:5/9/2016)... 2016 Elevay is currently known ... freedom for high net worth professionals seeking travel for ... connected world, there is still no substitute for a ... sealing your deal with a firm handshake. This is ... advantage of citizenship via investment programs like those offered ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. is ... has received AOAC Research Institute approval 061601. , “This is another AOAC-RI approval ... Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods ...
(Date:6/23/2016)... --  EpiBiome , a precision microbiome engineering company, today ... from Silicon Valley Bank (SVB). The financing will allow ... drug development efforts, as well as purchase additional lab ... been an incredible strategic partner to us – one ... provide," said Dr. Aeron Tynes Hammack , EpiBiome,s ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... In a ... Hospital in Denmark detail how a patient who developed lymphedema after being treated for ... The results could change the paradigm for dealing with this debilitating, frequent side effect ...
Breaking Biology Technology: